SG11201811431VA - Multispecific antibodies against cd40 and cd137 - Google Patents

Multispecific antibodies against cd40 and cd137

Info

Publication number
SG11201811431VA
SG11201811431VA SG11201811431VA SG11201811431VA SG11201811431VA SG 11201811431V A SG11201811431V A SG 11201811431VA SG 11201811431V A SG11201811431V A SG 11201811431VA SG 11201811431V A SG11201811431V A SG 11201811431VA SG 11201811431V A SG11201811431V A SG 11201811431VA
Authority
SG
Singapore
Prior art keywords
international
genmab
multispecific antibodies
yalelaan
utrecht
Prior art date
Application number
SG11201811431VA
Inventor
Isil Altintas
David Satijn
Rik Rademaker
Paul Parren
Friederike Gieseke
Ugur Sahin
Original Assignee
Genmab As
Biontech Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP2016066840 priority Critical
Application filed by Genmab As, Biontech Ag filed Critical Genmab As
Priority to PCT/EP2017/067924 priority patent/WO2018011421A1/en
Publication of SG11201811431VA publication Critical patent/SG11201811431VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966Animal cells
    • G01N33/56972White blood cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/526CH3 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 January 2018 (18.01.2018) W I P0 I P C T omit olo 0111 OH Imo lII ow (10) International Publication Number WO 2018/011421 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2017/067924 (22) International Filing Date: 14 July 2017 (14.07.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/EP2016/066840 14 July 2016 (14.07.2016) EP (71) Applicants: GENMAB A/S [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). BIONTECH AG [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). (72) Inventors: ALTINTAS, Isil; C/O Genmab B.V. Yalelaan 60, 3584-CM Utrecht (NL). SATIJN, David; C/O Gen- mab B.V. Yalelaan 60, 3584-CM Utrecht (NL). RADE- MAKER, Rik; C/O Genmab B.V. Yalelaan 60, 3584-CM Utrecht (NL). PARREN, Paul; Werdorperwaard 17, 3984 PR Odijk (NL). GIESEKE, Friederike; Am Romertor 5, 55116 Mainz (DE). SAHIN, Ugur; Philipp-von-Zabern- Platz 1, 55116 Mainz (DE). (74) Agent: GENMAB A/S; Kalvebod Brygge 43, 1560 Copen- hagen V (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 71' O (54) Title: MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137 O (57) : Multispecific antibodies binding to human CD40 and human CD137, methods for preparing 0 bodies, and methods of using such multispecific antibodies for therapeutic or other purposes. such multispecific anti-
SG11201811431VA 2016-07-14 2017-07-14 Multispecific antibodies against cd40 and cd137 SG11201811431VA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP2016066840 2016-07-14
PCT/EP2017/067924 WO2018011421A1 (en) 2016-07-14 2017-07-14 Multispecific antibodies against cd40 and cd137

Publications (1)

Publication Number Publication Date
SG11201811431VA true SG11201811431VA (en) 2019-01-30

Family

ID=59501399

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811431VA SG11201811431VA (en) 2016-07-14 2017-07-14 Multispecific antibodies against cd40 and cd137

Country Status (14)

Country Link
US (2) US11091557B2 (en)
EP (1) EP3484922A1 (en)
JP (1) JP2019533466A (en)
KR (1) KR20190028508A (en)
CN (1) CN109641959A (en)
AU (1) AU2017296095A1 (en)
BR (1) BR112019000512A2 (en)
CA (1) CA3030636A1 (en)
EA (1) EA201990293A1 (en)
IL (1) IL264142D0 (en)
MA (1) MA45672A (en)
MX (1) MX2018015853A (en)
SG (1) SG11201811431VA (en)
WO (1) WO2018011421A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003171TA (en) * 2015-01-08 2020-05-28 BioNTech SE Agonistic tnf receptor binding agents
KR20200064062A (en) * 2017-08-04 2020-06-05 젠맵 에이/에스 Binders that bind to PD-L1 and CD137 and uses thereof
CN112867733A (en) * 2018-10-19 2021-05-28 苏州丁孚靶点生物技术有限公司 anti-CD 137 antibodies and uses thereof
CN113454111A (en) * 2018-11-06 2021-09-28 健玛保 Antibody formulations
CN113226357A (en) * 2018-11-23 2021-08-06 斯特赖克药物公司 Bispecific conjugates
CN111269315A (en) * 2019-06-19 2020-06-12 北京智仁美博生物科技有限公司 Monoclonal antibodies against BCMA

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
KR970029803A (en) 1995-11-03 1997-06-26 김광호 Precharge Circuit of Semiconductor Memory Device
AT299938T (en) 1997-05-02 2005-08-15 Genentech Inc A process for the manufacture of multispecific antibodies having heteromultimes and common components
AU2753100A (en) 1999-02-03 2000-08-25 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU2001236621B2 (en) 2000-02-01 2006-06-15 Mycenax Biotech Inc. Cd40-binding apc-activating molecules
PT1326896E (en) 2000-10-02 2011-03-03 Novartis Vaccines & Diagnostic Human anti-cd40 antibodies
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
US20040018557A1 (en) 2002-03-01 2004-01-29 Immunomedics, Inc. Bispecific antibody point mutations for enhancing rate of clearance
US20030223989A1 (en) 2002-04-18 2003-12-04 Pluenneke John D. CD137 agonists to treat patients with IgE-mediated conditions
EP1523496B1 (en) 2002-07-18 2011-06-29 Merus B.V. Recombinant production of mixtures of antibodies
EP1638510B1 (en) 2003-07-01 2015-09-02 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CN1980957A (en) 2004-03-23 2007-06-13 比奥根艾迪克Ma公司 Receptor coupling agents and therapeutic uses thereof
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
CN101198698B (en) 2005-03-31 2014-03-19 中外制药株式会社 Process for production of polypeptide by regulation of assembly
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006317242A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AU2007227292B2 (en) 2006-03-17 2012-04-12 Biogen Ma Inc. Stabilized polypeptide compositions
SI1999154T1 (en) 2006-03-24 2013-01-31 Merck Patent Gmbh Engineered heterodimeric protein domains
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Method for manipulating immune lobulins
US20090074711A1 (en) 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AU2008265984B2 (en) 2007-06-21 2014-07-17 Macrogenics, Inc. Covalent diabodies and uses thereof
CA2700714C (en) 2007-09-26 2018-09-11 Ucb Pharma S.A. Dual specificity antibody fusions
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
ES2774337T3 (en) 2008-01-07 2020-07-20 Amgen Inc Method for manufacturing heterodimeric Fc molecules of antibodies using electrostatic conduction effects
US8927694B2 (en) 2008-11-18 2015-01-06 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
SI2786762T1 (en) 2008-12-19 2019-07-31 Macrogenics, Inc. Covalent diabodies and uses thereof
US20120134993A1 (en) 2009-03-27 2012-05-31 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
JP2012525149A (en) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Method for making heteromultimeric molecules
KR101224468B1 (en) 2009-05-20 2013-01-23 주식회사 파멥신 Bispecific antibody having a novel form and use thereof
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
JP5784624B2 (en) 2009-11-30 2015-09-24 ヤンセン バイオテツク,インコーポレーテツド Antibody Fc mutation with effector function removed
JP6184695B2 (en) 2009-12-04 2017-08-23 ジェネンテック, インコーポレイテッド Multispecific antibodies, antibody analogs, compositions and methods
GB201003293D0 (en) 2010-02-26 2010-04-14 Adjuvantix Ltd Cancer vaccine
TWI426920B (en) 2010-03-26 2014-02-21 Hoffmann La Roche Bispecific, bivalent anti-vegf/anti-ang-2 antibodies
NZ701825A (en) 2010-04-20 2016-06-24 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof
JP6022444B2 (en) 2010-05-14 2016-11-09 ライナット ニューロサイエンス コーポレイション Heterodimeric protein and method for producing and purifying it
AU2011290480B2 (en) 2010-08-16 2015-07-30 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
JP5758004B2 (en) 2010-08-24 2015-08-05 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Bispecific antibodies comprising Fv fragments stabilized by disulfides
CA2807269A1 (en) 2010-08-24 2012-03-01 Roche Glycart Ag Activatable bispecific antibodies
HUE047228T2 (en) 2010-11-05 2020-04-28 Zymeworks Inc Stable heterodimeric antibody design with mutations in the fc domain
CN102250246A (en) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 Bispecific antibody to VEGF/PDGFR beta and application thereof
EP3674320A3 (en) 2011-10-27 2020-08-12 Genmab A/S Production of heterodimeric proteins
KR102269650B1 (en) 2012-04-20 2021-06-28 메뤼스 엔.페. Methods and means for the production of Ig-like molecules
MX2015017487A (en) 2013-07-05 2016-03-21 Genmab As Humanized or chimeric cd3 antibodies.
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6144771B2 (en) 2012-11-21 2017-06-07 ファームアブシン インコーポレイテッド Dual-target antibody targeting VEGFR-2 and DLL4 and pharmaceutical composition comprising the same
ES2717530T3 (en) 2014-04-01 2019-06-21 Biontech Cell&Gene Therapies Gmbh Immunoreceptors and epitopes of Claudin-6 specific T cells
SG10202003171TA (en) 2015-01-08 2020-05-28 BioNTech SE Agonistic tnf receptor binding agents
MA41460A (en) 2015-02-03 2017-12-12 Oncomed Pharm Inc TNFRSF LIAISON AGENTS AND THEIR USES

Also Published As

Publication number Publication date
US20200062853A1 (en) 2020-02-27
BR112019000512A2 (en) 2019-04-24
WO2018011421A1 (en) 2018-01-18
CA3030636A1 (en) 2018-01-18
US20200247899A1 (en) 2020-08-06
CN109641959A (en) 2019-04-16
US11091557B2 (en) 2021-08-17
JP2019533466A (en) 2019-11-21
US11084882B2 (en) 2021-08-10
EA201990293A1 (en) 2019-07-31
MX2018015853A (en) 2019-08-21
AU2017296095A1 (en) 2019-01-17
KR20190028508A (en) 2019-03-18
MA45672A (en) 2019-05-22
EP3484922A1 (en) 2019-05-22
IL264142D0 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201808108XA (en) Synthesis of indazoles
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201810965YA (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
SG11201805649UA (en) Therapeutic anti-cd9 antibody
SG11201808686VA (en) Synthesis of indazoles
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201811432WA (en) Rna for cancer therapy
SG11201908088RA (en) Antibodies against pd-l1
SG11201806342SA (en) Glucagon and glp-1 co-agonists for the treatment of obesity
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201808592PA (en) Method for selection of high m6p recombinant proteins
SG11201804587QA (en) Isoindole compounds
SG11201806161TA (en) Antibodies for il-17c
SG11201806393QA (en) Use of gabaa receptor modulators for treatment of itch
SG11201908326YA (en) Methods of treating neurodegenerative diseases
SG11201909011PA (en) Niraparib compositions
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201804704PA (en) Compositions and methods for decreasing tau expression
SG11201809882XA (en) Pharmaceutical combinations for treating cancer